"RED BAND" CHEMICAL COMPANY, LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -0.3%

  £43,619,507 → £43,470,568

• Cash

  -26.3%

  £3,721,336 → £2,742,221

• Net assets

  -5.6%

  £13,561,194 → £12,799,990

• Employees

  +10%

  329 → 362

• Operating profit

  -151.2%

  £305,553 → -£156,406

• Profit before tax

  +65.7%

  -£1,327,050 → -£454,778

• Wages

  +8.2%

  £8,627,846 → £9,339,316

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Wbg (Audit) Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. "RED BAND" CHEMICAL COMPANY, LIMITED · parent
   1. Bonnybridge Pharmacy Company Limited 100% · Edinburgh · Dormant
   2. Woodside Pharmacy Limited 100% · Edinburgh · Dissolved

Significant events

• “Underlying operating profits remained broadly flat in 2024 as the improved gross profits that were generated as a result of better control of stock and improved buying margins were mostly offset by the continued Inflationary pressures which continue to hamper our recovery.”
• “To enable the business to manage the ever increasing cost of dispensing prescriptions, beta testing was completed in the final quarter of 2024 for our central dispensing hub in Broxburn. Following a hugely successful test, the business has now completed the full role out of centralised dispensing across all pharmacies, enabling them to be serviced by the central dispensing hub.”
• “In addition to these changes, we have also started to increase the number of Independent Prescriber pharmacists (IPs) that we employ across the business. Independent Prescribers can provide advice on and prescribe for a wider range of ailments than pharmacists who have not yet achieved the IP qualification.”
• “Whilst the changes outlined above will allow us to navigate the structural changes being seen across community pharmacy, we will however be significantly impacted by the changes in the budget in April 2025 in respect of Employers National Insurance.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.